Emergent BioSolutions | EBS - Current Assets


Emergent BioSolutions reported $679.5M in Current Assets for its fiscal quarter ending in December of 2023.





Current Assets Change Date
Acadia Pharmaceuticals USD 1.22B 128.53M Jun/2026
Akebia Therapeutics USD 243.48M 9.47M Mar/2026
ALKERMES USD 1.52B 164.26M Jun/2026
Alnylam Pharmaceuticals USD 4.62B 400.86M Jun/2026
Amarin USD 602.76M 23.26M Jun/2026
ANI Pharmaceuticals USD 747.08M 6.03M Mar/2026
BioMarin Pharmaceutical USD 4.61B 651.58M Mar/2026
Coherus Biosciences USD 206.71M 254.25M Dec/2025
Emergent BioSolutions USD 679.5M 41.3M Dec/2023
Exelixis USD 1.21B 234.65M Mar/2026
Glaxosmithkline GBP 17.76B 5.83B Mar/2026
Heron Therapeutics USD 228.98M 9.08M Mar/2026
Ionis Pharmaceuticals USD 2.49B 446.73M Jun/2026
Ironwood Pharmaceuticals USD 332.29M 58.11M Mar/2026
Lexicon Pharmaceuticals USD 186.03M 84.14M Mar/2026
Lonza CHF 8B 3.41B Dec/2025
Merck USD 35.02B 8.5B Mar/2026
Moderna USD 5.82B 45M Jun/2026
Myriad Genetics USD 289M 23.8M Jun/2026
Nektar Therapeutics USD 589.04M 322.77M Mar/2026
Neurocrine Biosciences USD 1.64B 798.6M Jun/2026
Pacira USD 615.21M 100.25M Jun/2026
Pfizer USD 41.36B 1.46B Jun/2026
PTC Therapeutics USD 2.62B 363.36M Jun/2026
Sanofi EUR 31.52B 1.36B Jun/2026
Sarepta Therapeutics USD 2.31B 228.06M Mar/2026
United Therapeutics USD 3.48B 611.7M Jun/2026
Vanda Pharmaceuticals USD 347.26M 20.23M Dec/2025